| Home : Vyera Pharmaceuticals Receives FDA Clearance To Initiate A Phase 1 Study Of A New Chemical Entity Designed As A Potential Treatment For Toxoplasmosis |
|
Nov 16
2018 |
Vyera Pharmaceuticals Receives FDA Clearance To Initiate A Phase 1 Study Of A New Chemical Entity Designed As A Potential Treatment For Toxoplasmosis |
|
NEW YORK, Nov. 15, 2018 /PRNewswire/ -- Vyera Pharmaceuticals, LLC (Vyera) announced it plans to initiate a Phase 1 single ascending dose (SAD) study of VYR-006, a novel dihydrofolate reductase (DHFR) inhibitor which Vyera discovered and is developing for the treatment of toxoplasmosis.... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/vyera-pharmaceuticals-receives-fda-clearance-to-initiate-a-phase-1-study-of-a-new-chemical-entity-designed-as-a-potential-treatment-for-toxoplasmosis-300751931.html |
| |
|
Related News
|
» Ohio family murders suspect arrested in Kentucky returning to Ohio to face charges
» World Institute of Kimchi: Kimchi lowers blood triglyceride level by 33%
|
